摘要
舌下特异性免疫治疗(SLIT)是一种新的特异性免疫治疗方法。大量的临床研究证实,SLIT可对过敏性哮喘和变应性鼻炎患者进行安全、有效的脱敏治疗,且在安全性上要明显优于皮下注射特异性免疫治疗(SCIT)。目前,SLIT已在欧洲、南非、澳大利亚、南亚和中东地区广泛应用。现综述探讨SLIT近年来的免疫机制,给药剂量与疗效的关系,临床疗效和长期疗效。
Sublingual immunotherapy（SLIT）is a new immunotherapy method which has been proved by many clinical studies that it can cure allergic asthma and rhinitis safely and effectively.Especially,SLIT is clearly better than subcutaneous immunotherapy（SCIT）in safety.At present,SLIT has been applied widely in Europe,South Africa,Australia,South Asia,and Middle East.Here is to discuss the mechanisms of SLIT,the relationships between allergen doses and efficacy,and the clinical efficacy and long efficacy.
出处
《医学综述》
2012年第9期1363-1366,共4页
Medical Recapitulate
